Short description
Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.
Description
Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. The company also focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions.
The DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed and the DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer, including the risk of sentinel lymph node positivity.
Castle Biosciences was founded in 2008 and is headquartered in Friendswood, Texas, United States.
Last funding
Nopepepe
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Friendswood, Texas, United States, North America
Founded on
January 1, 2008
Exited on
July 24, 2019
Went public on
July 24, 2019
Stock symbol
CSTL
Non-profit?
No
Acquired?
No
Employees count
501-1000
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noway Youcantaccess, Absolutely Noaccess, Noaccessforu, Nopepepe, Blurry Noaccess, Absolutely Noaccess, Nopepepe, Noaccess, Noway Youcantaccess, Absolutely Noaccess, Noaccess
Sign in for full access
Founders
Derek Maetzold